Chronic immune activation and inflammation in the pathogenesis of AIDS and cancer

Advances in Cancer Research

Volumn 84, Issue , 2002, Pages 231-276

  Dalgleish, Angus G ^a,b   O'Byrne, Ken J ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 2; NONSTEROID ANTIINFLAMMATORY AGENT; TAMOXIFEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANGIOGENESIS; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOLOGY; CANCER PREVENTION; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELLULAR IMMUNITY; ENVIRONMENTAL FACTOR; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNITY; INFLAMMATION; KAPOSI SARCOMA; MONKEY DISEASE; NONHUMAN; ONCOVIRINAE; PATHOGENESIS; PRECANCER; PRIORITY JOURNAL; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; VIRUS LOAD;

EID: 0036188120     PISSN: 0065230X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-230X(02)84008-8     Document Type: Review

References (314)

1. Pancytopaenia and hepatosplenomegaly in an AIDS patient responding to high dose steroids
2. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I
3. Serum vascular endothelial growth factor levels in various liver diseases
4. Correlation of T-helper secretory differentiation and types of antigen-presenting cells in squamous intraepithelial lesions of the uterine cervix
5. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus
6. Quantative analysis of Th1,Th2 and TGF-beta 1 cytokine expression in tumour, TIL and PBL of non-small cell lung cancer patients
7. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma
8. Evaluation of cell-mediated immunity and circulating immune complexes as prognostic indicators in cancer patients
9. Role of schistosomiasis in human bladder cancer: Evidence of association, aetiological factors, and basic mechanisms of carcinogenesis
10. Effects of insulin-like growth factor on neutrophil and monocyte functions in normal and septic states
11. Involvement of regulatory and catalytic subunits of phosphoinositide 3-kinase in NF-KB activation
12. Chemokine receptors as HIV-1 coreceptors: Roles in viral entry, tropism, and disease
13. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
14. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice
15. Molecular pathobiology and immunology of malignant mesothelioma
16. Detection of Epstein-Barr virus in invasive breast cancers
17. Human papillomavirus type 16 E2-specific T-helper lymphocyte responses in patients with cervical intraepithelial neoplasia
18. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV46
19. MHC antigens and cancer: Implications for T-cell surveillance
20. Introduction and historical perspective
21. COX-2 expression is induced by UVB exposure in human skin: Implications for the development of skin cancer
22. Insulin-like growth factor-binding protein-3 modulates expression of Bax and Bcl-2 and potentiates p53-independent radiation-induced apoptosis in human breast cancer cells
23. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alpha
24. Anergy in patients with gastric cancer
25. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for estrogen resistance
26. Status of long-term asymptomatic HIV-1 infection correlates with viral load but not with virus replication properties and cell tropism
27. Simian virus 40 and human tumors: It is time to study mechanisms
28. New molecular and epidemiological issues in mesothelioma role of SV40
29. Regulation of cell death protease caspase-9 by phosphorylation
30. Biological properties of interleukin-12 and its therapeutic use in persistent hepatitis B virus and hepatitis C virus infection
31. Nonsteroidal anti-inflammatory drugs and bladder cancer prevention
32. Genetic damage in exfoliated cells of the uterine cervix. Association and interaction between cigarette smoking and progression to malignant transformation?
33. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study
34. Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response
35. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31
36. Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients
37. Depressed cytolytic activity of peripheral blood mononuclear cells in unusually high paclitaxel concentrations: Reversal by IL-2 and IL-12
38. Not just another meeting: The coming of age of JAKs and STATs
39. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients
40. Human papillomavirus detection by the hybrid capture II assay: A reliable test to select women with normal cervical smears at risk for developing cervical lesions
41. The Th1-Th2 hypothesis of HIV infection: New insights
42. Self-organization, complexity and chaos: The new biology for medicine
43. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells
44. T helper cell activation and human retroviral pathogenesis
45. At the crossroads of inflammation and tumorigenesis
46. Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules
47. Viruses and cancer
48. The pathogenesis of AIDS: Classical and alternative views
49. The relevance of non-linear mathematics (chaos theory) to the treatment of cancer, the role of the immune response and the potential for vaccines
50. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus
51. Human immunodeficiency viruses
52. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-I
53. Induction of cell proliferation and apoptosis: Dependence on the dose of the inducer
54. Expression of the angiogenesis markers vascular endothelial growth factor-A, thrombospondin-1, and platelet-derived endothelial cell growth factor in human sporadic adrenocortical tumors: Correlation with genotypic alterations
55. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus-40 large T-antigen in human mesotheliomas
56. New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia
57. The etiology of Burkitt's lymphoma and the history of shaken dogmas
58. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt
59. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes
60. Intense vascular sprouting from rat femoral vein induced by prostaglandins E1 and E2
61. IGF-II/IGF-I receptor pathway up-regulates COX-2 mRNA expression and PGE2 synthesis in Caco-2 human colon carcinoma cells
62. Evasion of host immune responses by tumours and viruses
63. A novel role for TGF-beta and IL-10 in the induction of immune privilege
64. TGF beta-1 regulation of VEGF production by breast cancer cells
65. Cycloxygenase in biology and disease
66. Insulin-like growth factor I stimulates angiogenesis and the production of vascular endothelial growth factor
67. Prognostic factors for malignant mesothelioma in 142 patients: Validation of CALGB and EORTC prognostic scoring systems
68. Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: Possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver
69. Increased expression of cyclooxygenase-2 in rat lung tumors induced by the tobacco-specific nitrosamine 4-(methylnitrosamino) -4-(3-pyridyl)-1-butanone: The impact of a high-fat diet
70. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production
71. Induction of apoptosis in rat hepatocarcinoma cells by expression of IGF-I antisense c-DNA
72. Increased expression of epidermal growth factor receptor in rat pleural mesothelial cells correlates with carcinogenicity of mineral fibres
73. EGFR induced activation of NF-κB in mesothelial cells by asbestos is important in cell survival
74. Viral load in peripheral blood mononuclear cells as surrogate for clinical progression
75. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis
76. Neovascularization in hyperplastic, metaplastic, and potentially preneoplastic lesions of the bronchial mucosa
77. Renal cancer genetics: Von Hippel Lindau and other syndromes
78. Clinical applications of research on angiogenesis
79. Neoangiogenesis: A putative marker of malignancy in non-small cell lung cancer (NSCLC) development
80. The role of cytokines in tumor rejection
81. Interleukin-6 with its soluble receptor enhances the expression of insulin-like growth factor-I in osteoblasts
82. Transient increases in numbers of infectious cells in an HIV-infected chimpanzee following immune stimulation
83. Aspirin and reduced risk of esophageal carcinoma
84. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
85. Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice
86. Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes
87. Natural history of HLA expression during tumor development
88. Aspirin and the risk of colorectal cancer in women
89. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals
90. Cytotoxic CD4+ and CD8+ T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
91. Colonic luminal contents induce cyclooxygenase 2 transcription in human colon carcinoma cells
92. Wide range of viral load in healthy African green monkeys naturally infected with simian immunodeficiency virus
93. Mapping the Ig superantigen-binding site of HIV-1 gp120
94. Immune evasion of tumor cells using membrane-bound complement regulatory proteins
95. The role of immunologic and viral markers in predicting clinical outcome in HIV infection
96. Tuberculosis and cancer: Parallels in host responses and therapeutic approaches?
97. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
98. Tumor-mediated immunosuppression: Prevention by inhibitors of prostaglandin synthesis
99. IGF-I and insulin amplify IL-1 beta-induced nitric oxide and prostaglandin biosynthesis
100. Germ cell tumors of the testis overexpress wild-type p53
101. HLA mimicry by HIV-1 gp120 in the pathogenesis of AIDS
102. Does the HIV envelope induce a chronic graft-versus-host-like disease?
103. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
104. Immune strategies utilized by lentivirus-infected chimpanzees to resist progression to AIDS
105. Superantigens and retroviral infection: Insights from mouse mammary tumor virus
106. Reduction in cytokine production in colorectal cancer patients: Association with stage and reversal by resection
107. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis
108. Non-small cell lung cancer cycloxygenase activity and proliferation are inhibited by non-steroidal antiinflammatory drugs
109. Metaplastic polyp of the colon develops in response to inflammation
110. Transforming growth factor-beta stimulates urokinase expression in tumor-associated macrophages of the breast
111. Immune activation in cervical neoplasia: Cross-sectional association between plasma coluble interleukin 2 receptor levels and disease
112. Immune activation in cervical neoplasia: Cross-sectional association between plasma soluble interleukin 2 receptor levels and disease
113. Cyclosporine induces cancer progression by a cell-autonomous mechanism
114. The rate of progression to AIDS is independent of virus dose in simian immunodeficiency virus-infected macaques
115. Cyclooxygenase regulates human oropharyngeal carcinomas via the proinflammatory cytokine IL-6: A general role for inflammation?
116. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7
117. Association of latent membrane protein 1 and matrix metalloproteinase 9 with metastasis in nasopharyngeal carcinoma
118. A proposed molecular model for the carboxy terminus of HIV-1 gp120 showing structural features consistent with the presence of a T-cell alloepitope
119. Immunotherapy of advanced prostate cancer: A phase I/II trial using mycobacterium vaccae
120. Reproductive and infectious risk factors for invasive cervical cancer in Taiwan
121. Gene-modified tumor vaccine with therapeutic potential shifts tumor-specific T cell response from a type 2 to a type 1 cytokine profile
122. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: Up-regulation of interleukin 10 and down-regulation of interleukin 12 production
123. UV activates growth factor receptors via reactive oxygen intermediates
124. Profile of cytokine expression in nasopharyngeal carcinomas: A distinct expression of interleukin 1 in tumor and CD4+ T cells
125. A proinflammatory cytokine inhibits p53 tumor suppressor activity
126. Selective depletion in HIV infection of T cells that bear specific T cell receptor V beta sequences
127. Natural history of chronic hepatitis B and C
128. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective cohort study
129. High-grade inflammation in prostate cancer as a prognostic factor for biochemical recurrence after radical prostatectomy
130. Inverse modulation of IL-10 and IL-12 in the blood of women with preneoplastic lesions of the uterine cervix
131. Molecular evolution of the metaplasia-dysplasiaadenocarcinoma sequence in the esophagus
132. Asbestos causes translocation of p65 protein and increases NF-kappa B DNA binding activity in rat lung epithelial and pleural mesothelial cells
133. Asbestos causes translocation of p65 protein and increases NF-kappaB DNA binding activity in rat lung epithelial and pleural mesothelial cells
134. Altered CD3 chain and cytokine gene expression in tumor infiltrating T lymphocytes during the development of mesothelioma
135. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma
136. Delayed hypersensitivity skin testing as a prognostic indicator in patients with small cell lung cancer
137. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway
138. Production of interleukins 10 and 12 by peripheral blood mononuclear cells (PBMC) in chronic hepatitis C virus (HCV) infection
139. IRF-1 is an essential mediator in IFN-gamma-induced cell cycle arrest and apoptosis of primary cultured hepatocytes
140. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice
141. Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes
142. Diverse host responses and outcomes following simian immunodeficiency virus SIVmac239 infection in sooty mangabeys and rhesus macaques
143. Angiogenic squamous dysplasia in bronchi of individuals at high risk for lung cancer
144. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression
145. Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: Emerging mechanisms and shared strategies
146. Effects of tapering doses of oral prednisone on viral load among HIV-infected patients with unexplained weight loss
147. Crohn's disease and colorectal malignancy
148. Epstein-Barr virus-encoded poly(A)(-) RNA supports Burkitt's lymphoma growth through interleukin-10 induction
149. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV
150. Differences in angiogenic potential of classically vs alternatively activated macrophages
151. Helicobacter pylori, gastrin and cyclooxygenases in gastric cancer
152. Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumors
153. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
154. Antisense insulin-like growth factor I transferred into a rat hepatoma cell line inhibits tumorigenesis by modulating major histocompatibility complex I cell surface expression
155. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice
156. Delayed cutaneous hypersensitivity testing in untreated Hodgkin's disease using a standardised new device
157. Effect of anti-inflammatory drugs on overall risk of common cancer: Case-control study in general practice research database
158. Insulin-like growth factor-mediated muscle cell survival: Central roles for Akt and cyclin-dependent kinase inhibitor p21
159. HPV-16 E7 but not E6 oncogenic protein triggers both cellular immunosuppression and angiogenic processes
160. Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment
161. T helper 2-dominant antilymphoma immune response is associated with fatal outcome
162. Differences in the central major histocompatibility complex between humans and chimpanzees. Implications for development of autoimmunity and acquired immune deficiency syndrome
163. Genetic instabilities in human cancers
164. V3 variation in HIV-seropositive patients receiving a V3-targeted vaccine
165. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis
166. Cancer risk in patients with inflammatory bowel disease
167. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice
168. Expression of the Epstein-Barr virus BHRF1 gene, a homologue of Bcl-2, in nasopharyngeal carcinoma tissue
169. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression
170. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis
171. Serological and T-helper cell responses to human papillomavirus type 16 L1 in women with cervical dysplasia or cervical carcinoma and in healthy controls
172. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3
173. Akt stimulates the transactivation potential of the RelA/p65 subunit of NF-{kappa} B through utilization of the I{kappa} B kinase and activation of the mitogen activated protein kinase p38
174. Serum interleukin 6 concentrations in chronic hepatitis C patients before and after interferon-alpha treatment
175. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: Correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes
176. Chronic graft-versus-host disease
177. Carcinoma of the lung: Warts and all
178. Epstein-Barr virus-dependent lymphoproliferative disease: Critical role of IL-6
179. Previous lung disease and risk of lung cancer among men and women nonsmokers
180. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis
181. Esophageal cancers: Changing character, increasing incidence [news]
182. Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells
183. Association of HLA types A1-B8-DR3 and B27 with rapid and slow progression of HIV disease
184. Elevated transforming growth factor-beta concentration correlates with post-trauma immunosuppression
185. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms
186. Inhibition of cyclooxygenase-2 expression. An approach to preventing head and neck cancer
187. The secreted hepatitis B precore antigen can modulate the immune response to the nucleocapsid: A mechanism for persistence
188. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice
189. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: Growth inhibition by nonsteroidal anti-inflammatory drugs
190. Obesity and cancer risk: A Danish record-linkage study
191. Chronic mastitis and carcinoma of the breast
192. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis
193. Exercise training restores decreased cellular immune functions in obese Zucker rats
194. Decreased mitogen response of splenic lymphocytes in obese Zucker rats is associated with the decreased expression of glucose transporter 1 (GLUT-1)
195. TH1 and TH2 cells: Different patterns of lymphokine secretion lead to different functional properties
196. Cyclooxygenase-2 overexpression enhances lymphatic invasion and metastasis in human gastric carcinoma
197. A transformed view of cyclosporine
198. Study of risk factors for prostatic cancer
199. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes
200. Chemokine receptors and HIV-1 pathogenesis
201. The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease
202. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small cell lung cancer
203. Advanced colorectal cancer is associated with impaired interleukin 12 and enhanced interleukin 10 production
204. Immunosuppression in patients with Barrett's esophagus
205. Changes to the cytokine microenvironment in the genital tract mucosa of HIV+ women
206. Aspirin and the prevention of colorectal cancer: A review of the evidence
207. Immunomodulation by ultraviolet light: Clinical studies and biological effects
208. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation
209. Inhibition of hamster mesothelioma tumorigenesis by an antisense expression plasmid to the insulin-like growth factor-I receptor
210. Tumors of the immunocompromised patient
211. Biphasic effect of transforming growth factor factor-beta 1 on in vitro angiogenesis
212. Immune selection in neoplasia: Towards a microevolutionary model of cancer development
213. UVB-induced epidermal growth factor receptor phosphorylation is critical for downstream signaling and keratinocyte survival
214. Her-2/neu overexpression induces NF-kappaB via a PI3-kinase/Akt pathway involving calpein-mediated degradation of IkappaB-alpha that can be inhibited by the tumour suppressor PTEN
215. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions
216. The prognostic significance in HIV infection of immune activation represented by cell surface antigen and plasma activation marker changes
217. T-cell antigen receptor V beta subsets are not preferentially deleted in AIDS
218. The influence of potential biases on the risk of breast tumors among women who received radiotherapy for acute postpartum mastitis
219. Co-presentation of natural HIV-agonist and antagonist ligands fails to induce the T cell receptor signalling cascade
220. Gene transfer of transforming growth factor-beta 1 prolongs murine cardiac allograft survival by inhibiting cell mediated immunity
221. Consilience across evolving dysplasias affecting myeloid, cervical, esophageal, gastric and liver cells: Common themes and emerging patterns
222. T-cell abnormality and defective interleukin-2 production in patients with carcinoma of the urinary bladder with schistosomiasis
223. Ovarian cell differentiation: A cascade of multiple hormones, cellular signals, and regulated genes
224. In vivo anergy reversal with cimetidine in patients with cancer
225. TGF-beta and colorectal carcinogenesis
226. Hormones, peripherally activated prohormones and regulation of the Th1/Th2 balance
227. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
228. Malignant melanoma. Delayed hypersensitivity skin testing
229. Platelet-derived growth factor increases the activity of the promoter of the insulin-like growth factor-I (IGF-I) receptor gene
230. High cyclooxygenase-2 expression in stage IB cervical cancer with lymph node metastasis or parametrial invasion
231. Nicotine stereoisomers and cotinine stimulate prostaglandin E2 but inhibit thromboxane B2 and leukotriene E4 syntheses in whole blood
232. Synergistic induction of cyclooxygenase-2 by transforming growth factor-betal and epidermal growth factor inhibits apoptosis in epithelial cells
233. Effect of hypobaric hypoxia on immune function in albino rats
234. High viral load in lymph nodes and latent human immunodeficiency virus (HIV) in peripheral blood cells of HIV-1-infected chimpanzees
235. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients
236. Abnormal signal transduction by T cells of mice with parental tumors is not seen in mice bearing IL-2 secreting tumors
237. Antiestrogens
238. Helicobacter pylori infection induces cyclooxygenase-2 expression in human gastric mucosa
239. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice
240. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo
241. Lymphocyte function in wound healing and following injury
242. Correlation between viral load measurements and outcome in clinical trials of antiviral drugs
243. Aspirin use and lung, colon, and breast cancer incidence in a prospective study
244. Augmented myocardial ischaemia by nicotine - Mechanisms and their possible significance
245. The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid
246. Th1 cytokine patternsd in cervical human papillomavirus infection
247. Antagonista of cytotoxic T-lymphocyte activation by soluble CD8
248. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles
249. Allogeneic leukocytes as a possible factor in induction of AIDS in homosexual men
250. T helper cell immune dysfunction in asymptomatic. HIV-1-seropositive individuals: The role of TH1-TH2 cross-regulation
251. HIV gp120 plus specific peptides are recognized in a similar manner to specific HLA plus peptide by HLA-restricted antigen-specific T-cell lines
252. The gp120 envelope of HIV-1 binds peptides in a similar manner to human leukocyte antigens
253. Cutaneous wound healing
254. Human papillomavirus infection with particular reference to genital disease
255. Genetic susceptibility to tobacco carcinogenesis
256. Interrelation of lymphocyte subpopulations in peripheral blood under cervical papillomavirus infection
257. Predominance of TH1 response in tumor-bearing mice and cancer patients treated with AS101
258. Immune evasion by tumours: Involvement of the CD95 (APO-1/Fas) system and its clinical implications
259. The American Cancer Society Prospective Study
260. Inhibition of cyclooxygenase: A novel approach to cancer prevention
261. Runt-related gene 2 in endothelial cells: Inducible expression and specific regulation of cell migration and invasion
262. Epstein-Barr virus and gastric carcinoma
263. The effect of Helicobacter pylori on cell proliferation and apoptosis in gastric epithelial cell lines
264. Activation of matrix metalloproteinase-2 in human breast cancer cells overexpressing cyclooxygenase-1 or -2
265. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II)
266. NF-κB: A lesson in family values
267. Aspirin use and reduced risk of fatal colon cancer
268. Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor JTE-522
269. Detection of type-2-like T-helper cells in hepatitis C virus infection: Implications for hepatitis C virus chronicity
270. Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines
271. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2
272. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential
273. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
274. Antiproliferative effects of retinoic acid/interferon in cervical carcinoma cell lines: Cooperative growth suppression of IRF-1 and p53
275. Soluble interleukin 2 receptor levels and cervical neoplasia: Results from a population-based case-control study in Costa Rica
276. The role of cyclic AMP and oxygen intermediates in the inhibition of cellular immunity in cancer
277. Apoptosis and proliferation of epithelial cells in papillomaviral and chlamydial cervicitis
278. Cyclo-oxygenase 2 and breast cancer prevention. Nonsteroidal anti-inflammatory agents are worth testing in breast cancer
279. Cyclooxygenases 1 and 2
280. Tumour vaccines
281. Genetic alterations during colorectal-tumor development
282. Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity
283. Transforming growth factor type induces monocyte chemotaxis and growth factor production
284. Normal pharmacologically-induced, but decreased regenerative liver growth in interleukin-6-deficient (IL-6(-/-)) mice
285. Detection of Epstein-Barr virus in esophageal squamous cell carcinoma in Taiwan
286. IGF-I induction of p53 requires activation of MAP kinase in cardiac muscle cells
287. Epidermal growth factor receptor-dependent Akt activation by oxidative stress enhances cell survival
288. Regulation of local host-mediated anti-tumor mechanisms by cytokines: Direct and indirect effects on leukocyte recruitment and angiogenesis
289. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: A possible mechanism for receptor overexpression in breast cancer
290. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene
291. Abnormal intracellular IL-2 and interferon-gamma (IFN-gamma) production as HIV-1-assocated markers of immune dysfunction
292. Low CD4 counts rather than superantigenic-like effects account for differences in expressed T-cell receptor (TCR) repertoires between HIV-1 seropositive long-term non-progressors and individuals with progressive disease
293. Kaposi's sarcoma herpesvirus as a new paradigm for virus-induced oncogenesis
294. Inflammatory cell infiltrate in the cervix as a predictor of residual cervical intraepithelial neoplasia after conization
295. Helicobacter pylori: From the benign to the malignant
296. Expression of cyclooxygenase-2 in human lung carcinoma
297. Joint effect of insulin-like growth factors and mutagen sensitivity in lung cancer risk
298. Activation of the insulin-like growth factor-I receptor inhibits tumor necrosis factor-induced cell death
299. Epstein-Barr virus (EBV)-infected cells were frequently but dispersely detected in T-cell lymphomas of various types by in situ hybridization with an RNA probe specific to EBV-specific nuclear antigen 1
300. IF-Nalpha/beta promotes cell survival by activating NF-kappaB through phosphatidyl inositol-3 kinase and Akt
301. Regulation of cyclooxygenase-2 expression in renal medulla by tonicity in vivo and in vitro
302. Inhibition of COX-2 and induction of apoptosis: Two determinants of nonsteroidal anti-inflammatory drugs' chemopreventive efficacies in mouse lung tumorigenesis
303. Tumor suppressor p53 as a component of the tumor necrosis factor-induced, protein kinase PKR-mediated apoptotic pathway in human promonocytic U937 cells
304. HIV and HLA similarity
305. Involvement of tyrosine kinases on cyclooxygenase expression and prostaglandin E2 production in human gingival fibroblasts stimulated with interleukin-1 beta and epidermal growth factor
306. Alterations in T cell receptor and signal transduction molecules in melanoma patients
307. Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells
308. Dihydroxy bile acids activate the transcription of cyclooxygenase-2
309. Epstein-Barr virus infection, salted fish and nasopharyngeal carcinoma. A case control study in Southern China
310. HER-2/neu blocks tumour necrosis factor-induced apoptosis via the Akt/NF-κB pathway
311. p53 induces TAP1 and enhances the transport of MHC class I peptides
312. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: Expression of the transforming BARF1 gene